Liver disease in recipients of long-functioning renal allografts.
After noting that hepatic failure was the leading cause of death in our transplant recipients whose renal allografts had functioned for more than five years, we reviewed retrospectively the post-transplant course of these patients to assess the long-term effect of liver disease in this population. Sufficient data was available to evaluate 184 of 217 long-term survivors (85%). Twenty-six patients (14%) experienced a doubling of SGOT and/or SGPT of greater than six months' duration and were defined as having chronic liver disease. The etiology of chronic liver disease was identified in 14 patients (54%), of whom 11 were HBsAg positive. Evidence of chronic hepatitis developed in only six of 26 patients (22%) during the first four years post transplant. Once enzyme abnormalities occurred, they were unremitting until death or end of the study in 73% of patients. Actuarial survival of patients with chronic liver disease was markedly decreased compared to long-surviving transplanted controls. Ten of the 12 deaths in patients with hepatocellular abnormalities were due to hepatic failure, of which eight occurred in the setting of extrahepatic sepsis. Chronic liver disease is a late complication of transplantation and is associated with significant mortality due to an increased susceptibility to overwhelming sepsis.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001379:Azathioprine / Q000009:adverse effects; D001424:Bacterial Infections / Q000150:complications; D002353:Carrier State; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000401:mortality / Q000628:therapy; D016030:Kidney Transplantation; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D008297:Male; D012189:Retrospective Studies; D012306:Risk; D014184:Transplantation, Homologous / Q000009:adverse effects
D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001379:Azathioprine